{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:24:39Z","timestamp":1783398279224,"version":"3.54.6"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T00:00:00Z","timestamp":1607558400000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pharmacosmos UK Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Intravenous iron is often used to treat iron deficiency anaemia in non-dialysis chronic kidney disease (ND-CKD), but the optimal dosing regimen remains unclear. We evaluated the impact of high- versus low-dose intravenous iron isomaltoside on the probability of retreatment with intravenous iron in iron-deficient ND-CKD patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This real-world, prospective, observational study collected data from 256 ND-CKD patients treated for anaemia in the UK. Following an initial course of iron isomaltoside, patients were followed for \u226512\u2009months. Iron dose and the need for retreatment were determined at the investigators\u2019 discretion. The primary study outcome was the need for retreatment at 52\u2009weeks compared between patients who received &gt;1000\u2009mg of iron during Course 1 and those who received \u22641000\u2009mg. Safety was evaluated through adverse drug reactions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The probability of retreatment at Week 52 was significantly lower in the &gt;1000\u2009mg iron group (<jats:italic>n<\/jats:italic>\u2009=\u200958) versus the \u22641000\u2009mg group (<jats:italic>n<\/jats:italic>\u2009=\u2009198); hazard ratio (95% confidence interval [CI]): 0.46 (0.20, 0.91); <jats:italic>p<\/jats:italic>\u2009=\u20090.012. Mean (95% CI) haemoglobin increased by 6.58 (4.94, 8.21) g\/L in the \u22641000\u2009mg group and by 10.59 (7.52, 13.66) g\/L in the &gt;1000\u2009mg group (<jats:italic>p<\/jats:italic>\u2009=\u20090.024). Changes in other blood and iron parameters were not significantly different between the two groups. Administering &gt;1000\u2009mg of iron isomaltoside saved 8.6 appointments per 100 patients compared to \u22641000\u2009mg. No serious adverse drug reactions were reported. Of the patients who received \u22641000\u2009mg of iron in this study, 82.3% were eligible for a dose &gt;1000\u2009mg.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The &gt;1000\u2009mg iron isomaltoside regimen reduced the probability of retreatment, achieved a greater haemoglobin response irrespective of erythropoiesis-stimulating agent treatment, and reduced the total number of appointments required, compared to the \u22641000\u2009mg regimen. Many of the patients who received \u22641000\u2009mg of iron were eligible for &gt;1000\u2009mg, indicating that there was considerable underdosing in this study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02546154\">NCT02546154<\/jats:ext-link>, 10 September 2015.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-020-02180-2","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T11:03:40Z","timestamp":1607598220000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["NIMO-CKD-UK: a real-world, observational study of iron isomaltoside in patients with iron deficiency anaemia and chronic kidney disease"],"prefix":"10.1186","volume":"21","author":[{"given":"Philip A.","family":"Kalra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Spyridon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Davison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lawman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Mikhail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Reaich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Pritchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran","family":"McCafferty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,10]]},"reference":[{"issue":"2","key":"2180_CR1","first-page":"161","volume":"19","author":"L Gotloib","year":"2006","unstructured":"Gotloib L, Silverberg D, Fudin R, Shostak A. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol. 2006;19(2):161\u20137.","journal-title":"J Nephrol."},{"issue":"9","key":"2180_CR2","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1185\/030079904X2763","volume":"20","author":"W McClellan","year":"2004","unstructured":"McClellan W, Aronoff SL, Bolton WK, Hood S, Lorber DL, Tang KL, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 2004;20(9):1501\u201310.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"2180_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0084943","volume":"9","author":"ME Stauffer","year":"2014","unstructured":"Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLoS One. 2014;9(1):e84943.","journal-title":"PLoS One"},{"issue":"1","key":"2180_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12882-016-0312-9","volume":"17","author":"D Eriksson","year":"2016","unstructured":"Eriksson D, Goldsmith D, Teitsson S, Jackson J, van Nooten F. Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia. BMC Nephrol. 2016;17(1):97.","journal-title":"BMC Nephrol"},{"issue":"3","key":"2180_CR5","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/sj.ki.5000105","volume":"69","author":"CP Kovesdy","year":"2006","unstructured":"Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, Anderson JE. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int. 2006;69(3):560\u20134.","journal-title":"Kidney Int"},{"issue":"13 Suppl 8","key":"2180_CR6","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.2146\/ajhp070181","volume":"64","author":"TC Dowling","year":"2007","unstructured":"Dowling TC. Prevalence, etiology, and consequences of anemia and clinical and economic benefits of anemia correction in patients with chronic kidney disease: an overview. Am J Health Syst Pharm. 2007;64(13 Suppl 8):S3\u20137.","journal-title":"Am J Health Syst Pharm"},{"key":"2180_CR7","unstructured":"National Institute for Health and Care Excellence (NICE). Chronic kidney disease: managing anaemia. NICE guideline (NG8). June 2015. www.nice.org.uk\/guidance\/ng8. Accessed 19 Aug 2019."},{"issue":"4","key":"2180_CR8","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1093\/ndt\/gfv293","volume":"31","author":"PA Kalra","year":"2016","unstructured":"Kalra PA, Bhandari S, Saxena S, Agarwal D, Wirtz G, Kletzmayr J, et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. Nephrol Dial Transplant. 2016;31(4):646\u201355.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"2180_CR9","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1053\/j.ajkd.2016.04.018","volume":"68","author":"D Shepshelovich","year":"2016","unstructured":"Shepshelovich D, Rozen-Zvi B, Avni T, Gafter U, Gafter-Gvili A. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: an updated systematic review and meta-analysis. Am J Kidney Dis. 2016;68(5):677\u201390.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"2180_CR10","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1053\/j.gastro.2011.06.005","volume":"141","author":"R Evstatiev","year":"2011","unstructured":"Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, Bokemeyer B, et al. FERGI study group. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011;141(3):846\u201353.","journal-title":"Gastroenterology."},{"key":"2180_CR11","doi-asserted-by":"publisher","first-page":"763576","DOI":"10.1155\/2015\/763576","volume":"2015","author":"TA Koch","year":"2015","unstructured":"Koch TA, Myers J, Goodnough LT. Intravenous iron therapy in patients with iron deficiency anemia: dosing considerations. Anemia. 2015;2015:763576.","journal-title":"Anemia."},{"issue":"5","key":"2180_CR12","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1056\/NEJMoa1810742","volume":"380","author":"IC Macdougall","year":"2019","unstructured":"Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, et al. PIVOTAL investigators and committees. Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med. 2019;380(5):447\u201358.","journal-title":"N Engl J Med"},{"issue":"4","key":"2180_CR13","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1093\/ndt\/gft251","volume":"29","author":"JE Onken","year":"2014","unstructured":"Onken JE, Bregman DB, Harrington RA, Morris D, Buerkert J, Hamerski D, et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Nephrol Dial Transplant. 2014;29(4):833\u201342.","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"2180_CR14","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","volume":"29","author":"IC Macdougall","year":"2014","unstructured":"Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, et al. FIND-CKD study investigators. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant. 2014;29(11):2075\u201384.","journal-title":"Nephrol Dial Transplant"},{"key":"2180_CR15","unstructured":"Monofer\u00ae (iron isomaltoside 1000). Summary of product characteristics. \u00a9 Pharmacosmos UK Limited. May 2020."},{"key":"2180_CR16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/IJNRD.S89704","volume":"9","author":"PA Kalra","year":"2016","unstructured":"Kalra PA, Bhandari S. Efficacy and safety of iron isomaltoside (Monofer\u00ae) in the management of patients with iron deficiency anemia. Int J Nephrol Renovasc Dis. 2016;9:53\u201364.","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"5","key":"2180_CR17","doi-asserted-by":"publisher","first-page":"589","DOI":"10.5301\/JN.2011.6248","volume":"24","author":"B Wikstr\u00f6m","year":"2011","unstructured":"Wikstr\u00f6m B, Bhandari S, Barany P, Kalra PA, Ladefoged S, Wilske J, Thomsen LL. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease. J Nephrol. 2011;24(5):589\u201396.","journal-title":"J Nephrol"},{"issue":"9","key":"2180_CR18","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1093\/ndt\/gfv096","volume":"30","author":"S Bhandari","year":"2015","unstructured":"Bhandari S, Kalra PA, Kothari J, Kalra PA, Ladefoged S, Wilske J, Thomsen LL. A randomized, open-label trial of iron isomaltoside 1000 (Monofer\u00ae) compared with iron sucrose (Venofer\u00ae) as maintenance therapy in haemodialysis patients. Nephrol Dial Transplant. 2015;30(9):1577\u201389.","journal-title":"Nephrol Dial Transplant"},{"key":"2180_CR19","doi-asserted-by":"publisher","unstructured":"Bhandari A, Kalra PA, Berkowitz M, Belo D, Thomsen LL, Wolf M. A randomized, open-label, comparative trial of iron isomaltoside 1000 and iron sucrose in chronic kidney disease patients (FERWON-NEPHRO). Nephrol Dial Transplant. 2020;\u00a0https:\/\/doi.org\/10.1093\/ndt\/gfaa011.","DOI":"10.1093\/ndt\/gfaa011"},{"issue":"12","key":"2180_CR20","doi-asserted-by":"publisher","first-page":"310","DOI":"10.5414\/CN108941","volume":"86","author":"P Biggar","year":"2016","unstructured":"Biggar P, Leistikow F, Walper A. A prospective observational study of effectiveness and safety of iron isomaltoside in patients with chronic renal failure and iron deficiency anemia. Clin Nephrol. 2016;86(12):310\u20138.","journal-title":"Clin Nephrol"},{"issue":"4","key":"2180_CR21","doi-asserted-by":"publisher","first-page":"246","DOI":"10.5414\/CN109474","volume":"91","author":"G Jensen","year":"2019","unstructured":"Jensen G, G\u00f8ransson LG, Fernstr\u00f6m A, Furuland H, Christensen JH. Treatment of iron deficiency in patients with chronic kidney disease: a prospective observational study of iron isomaltoside (NIMO Scandinavia). Clin Nephrol. 2019;91(4):246\u201353.","journal-title":"Clin Nephrol"},{"issue":"2","key":"2180_CR22","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3747\/pdi.2018.00125","volume":"39","author":"C Sivakumar","year":"2019","unstructured":"Sivakumar C, Jubb VM, Lamplugh A, Bhandari S. Safety of intravenous iron \u2013 Cosmofer and Monofer therapy in peritoneal dialysis and non-dialysis-dependent chronic kidney disease patients. Perit Dial Int. 2019;39(2):192\u20135.","journal-title":"Perit Dial Int"},{"key":"2180_CR23","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO). Clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2:279\u2013335."},{"issue":"7","key":"2180_CR24","first-page":"301","volume":"100","author":"AM Ganzoni","year":"1970","unstructured":"Ganzoni AM. Intravenous iron-dextran: therapeutic and experimental possibilities. Schweiz Med Wochenschr. 1970;100(7):301\u20133.","journal-title":"Schweiz Med Wochenschr"},{"issue":"1","key":"2180_CR25","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12955-015-0257-x","volume":"13","author":"S Acaster","year":"2015","unstructured":"Acaster S, Dickerhoof R, DeBusk K, Bernard K, Strauss W, Allen LF. Qualitative and quantitative validation of the FACIT-fatigue scale in iron deficiency anemia. Health Qual Life Outcomes. 2015;13(1):60.","journal-title":"Health Qual Life Outcomes"},{"key":"2180_CR26","unstructured":"Aranesp\u00ae (darbepoetin alfa). Summary of product characteristics. \u00a9 Amgen Limited. November 2019."},{"key":"2180_CR27","doi-asserted-by":"publisher","first-page":"4585164","DOI":"10.1155\/2017\/4585164","volume":"2017","author":"SO Frigstad","year":"2017","unstructured":"Frigstad SO, Haaber A, Bajor A, Fallingborg J, Hammarlund P, Bonderup OK, et al. The NIMO Scandinavian study: a prospective observational study of iron isomaltoside treatment in patients with iron deficiency. Gastroenterol Res Pract. 2017;2017:4585164.","journal-title":"Gastroenterol Res Pract"},{"key":"2180_CR28","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2147\/CEOR.S139525","volume":"9","author":"RF Pollock","year":"2017","unstructured":"Pollock RF, Muduma G. A budget impact analysis of parenteral iron treatments for iron deficiency anemia in the UK: reduced resource utilization with iron isomaltoside 1000. Clinicoecon Outcomes Res. 2017;9:475\u201383.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"12","key":"2180_CR29","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1080\/17425247.2017.1393412","volume":"14","author":"RF Pollock","year":"2017","unstructured":"Pollock RF, Muduma G. Intravenous iron treatments for iron deficiency anemia in inflammatory bowel disease: a budget impact analysis of iron isomaltoside 1000 (Monofer) in the UK. Expert Opin Drug Deliv. 2017;14(12):1439\u201346.","journal-title":"Expert Opin Drug Deliv"},{"issue":"12","key":"2180_CR30","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1007\/s12325-018-0827-5","volume":"35","author":"RF Pollock","year":"2018","unstructured":"Pollock RF, Muduma G. An economic evaluation of iron isomaltoside 1000 versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in Denmark. Adv Ther. 2018;35(12):2128\u201337.","journal-title":"Adv Ther"},{"key":"2180_CR31","doi-asserted-by":"publisher","first-page":"501","DOI":"10.2147\/TCRM.S25882","volume":"7","author":"S Bhandari","year":"2011","unstructured":"Bhandari S. Update of a comparative analysis of cost minimization following the introduction of newly available intravenous iron therapies in hospital practice. Ther Clin Risk Manag. 2011;7:501\u20139.","journal-title":"Ther Clin Risk Manag"},{"key":"2180_CR32","unstructured":"National Health Service (NHS). Clinical guide for the management of remote consultations and remote working in secondary care during the coronavirus pandemic. Version 1. 27 March 2020."},{"key":"2180_CR33","unstructured":"Centers for Disease Control and Prevention (CDC) website. Healthcare facilities: managing operations during the COVID-19 pandemic. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/guidance-hcf.html. Accessed 9 Nov 2020."},{"issue":"1","key":"2180_CR34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.7326\/0003-4819-153-1-201007060-00252","volume":"153","author":"SC Palmer","year":"2010","unstructured":"Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010;153(1):23\u201333.","journal-title":"Ann Intern Med"},{"key":"2180_CR35","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s12882-017-0688-1","volume":"18","author":"A Mikhail","year":"2017","unstructured":"Mikhail A, Brown C, Williams JA, Mathrani V, Shrivastava R, Evans J, et al. Renal association clinical practice guideline on anaemia of chronic kidney disease. BMC Nephrol. 2017;18:345.","journal-title":"BMC Nephrol"},{"issue":"3","key":"2180_CR36","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1525-139X.2008.00435.x","volume":"21","author":"NV Dahl","year":"2008","unstructured":"Dahl NV, Henry DH, Coyne DW. Thrombosis with erythropoietic stimulating agents \u2013 does iron-deficient erythropoiesis play a role? Semin Dial. 2008;21(3):210\u20131.","journal-title":"Semin Dial"},{"issue":"1","key":"2180_CR37","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/jcpt.12218","volume":"40","author":"AM Hazara","year":"2015","unstructured":"Hazara AM, Bhandari S. Intravenous iron administration is associated with reduced platelet counts in patients with chronic kidney disease. J Clin Pharm Ther. 2015;40(1):20\u20133.","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"2180_CR38","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/ajh.22262","volume":"87","author":"DH Henry","year":"2012","unstructured":"Henry DH, Dahl NV, Auerbach MA. Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron. Am J Haematol. 2012;87(3):308\u201310.","journal-title":"Am J Haematol"},{"key":"2180_CR39","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2147\/PROM.S169653","volume":"9","author":"WE Strauss","year":"2018","unstructured":"Strauss WE, Auerbach M. Health-related quality of life in patients with iron deficiency anemia: impact of treatment with intravenous iron. Patient Relat Outcome Meas. 2018;9:285\u201398.","journal-title":"Patient Relat Outcome Meas"},{"key":"2180_CR40","volume-title":"Directive 2001\/20\/EC of the European Parliament and of the Council Article 2(c)","author":"European Medicines Agency","year":"2001","unstructured":"European Medicines Agency. Directive 2001\/20\/EC of the European Parliament and of the Council Article 2(c). 2001."}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-02180-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-020-02180-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-02180-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T11:10:08Z","timestamp":1607598608000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-020-02180-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2180"],"URL":"https:\/\/doi.org\/10.1186\/s12882-020-02180-2","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"12 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Health Research Authority and the Regional Ethics Committee in the UK (reference: 15\/EM\/0303) approved the study and all subsequent protocol amendments. All study participants gave written informed consent before inclusion into the study, and the study was performed in accordance with Good Pharmacovigilance Practices and the European Medicines Agency criteria for non-interventional studies [].","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Pharmacosmos UK Ltd. sponsored the study. PAK and SB have received consultancy fees, speaker honoraria and educational grants from Pharmacosmos and Vifor Pharma. MS is an employee of Pharmacosmos UK Ltd. RD has received consultancy fees, speaker honoraria and educational grants from Pharmacosmos. DR has received consultancy fees and educational grants from Pharmacosmos. SL has received consultancy fees from Pharmacosmos. AM and KM have received consultancy fees from Pharmacosmos and Vifor Pharma. NP has received speaker honoraria from Pharmacosmos. JM has no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"539"}}